Michael Schmidt (Guggenheim) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Michael Schmidt's stock ratings?

About 51% of Michael's ratings were profitable over a one-year hold, with an average return of +11.5% per rating, measured by 13Foresight from historical prices.

Q: How is Michael ranked?

Michael Schmidt is ranked #2023 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Michael Schmidt

GUGG

Michael Schmidt

Guggenheim

Wall Street Analyst

★★☆☆☆

#2023

on 13Foresight · ranked by our own returns

52%

Success Rate

+11.6%

Average Return

34 of 66 calls profitable · -28164.3% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 52% of Michael Schmidt's ratings turned a profit when each position was held for 2 year — averaging +11.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

130 Buy 10 Hold 0 Sell

Michael's Stock Coverage 60 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return
ENGN enGene Holdings	Jun 16, 2026	HOLD	Buy +481.4% avg upside 13 analysts	—	+0.0%
ONC BeOne Medicines	Jun 15, 2026	BUY	Strong Buy +28.4% avg upside 28 analysts	$420.00 55.53% Upside	-2.1%
INCY Incyte	Jun 15, 2026	BUY	Buy +1.0% avg upside 47 analysts	$136.00 38.50% Upside	-2.9%
ELVN Enliven Therapeutics	Jun 12, 2026	BUY	Strong Buy +7.1% avg upside 14 analysts	$80.00 77.39% Upside	-5.8%
TNGX Tango Therapeutics	Jun 09, 2026	BUY	Strong Buy +24.3% avg upside 14 analysts	$32.00 14.32% Upside	+2.3%
ADCT ADC Therapeutics	Jun 05, 2026	BUY	Buy +450.4% avg upside 12 analysts	$10.00 817.43% Upside	+7.8%
AVBP ArriVent BioPharma, Inc.	Jun 01, 2026	BUY	Strong Buy +37.0% avg upside 15 analysts	$45.00 41.77% Upside	+2.2%
RVMD Revolution Medicines	Jun 01, 2026	BUY	Strong Buy -12.3% avg upside 32 analysts	$205.00 25.68% Upside	-3.6%
GMAB Genmab	May 25, 2026	BUY	Buy +38.3% avg upside 26 analysts	$40.00 58.20% Upside	·
IMNM Immunome	May 12, 2026	BUY	Strong Buy +83.0% avg upside 16 analysts	$35.00 86.77% Upside	-18.3%
CTMX CytomX Therapeutics	May 07, 2026	BUY	Strong Buy +269.6% avg upside 21 analysts	$15.00 408.52% Upside	-24.8%
VSTM Verastem	May 07, 2026	BUY	Strong Buy +260.2% avg upside 23 analysts	$14.00 239.74% Upside	-29.3%
XFOR X4 Pharmaceuticals	May 06, 2026	BUY	Strong Buy +491.4% avg upside 15 analysts	$12.00 184.41% Upside	-6.9%
COGT Cogent Biosciences	May 06, 2026	BUY	Strong Buy +7.1% avg upside 26 analysts	$45.00 30.34% Upside	-4.6%
NBTX Nanobiotix	May 05, 2026	BUY	Strong Buy -8.5% avg upside 5 analysts	$36.00 0.65% Downside	+2.0%
ZNTL Zentalis Pharmaceuticals	Apr 10, 2026	BUY	Buy +292.3% avg upside 16 analysts	$10.00 170.35% Upside	-45.8%
GLUE Monte Rosa Therapeutics	Mar 18, 2026	BUY	Strong Buy +27.5% avg upside 14 analysts	$30.00 63.91% Upside	+16.2%
ERAS Erasca	Mar 13, 2026	BUY	Strong Buy +39.0% avg upside 14 analysts	$20.00 46.33% Upside	+2.6%
FHTX Foghorn Therapeutics	Mar 11, 2026	BUY	Strong Buy +187.5% avg upside 17 analysts	$12.00 189.20% Upside	-24.2%
EXEL Exelixis	Feb 10, 2026	HOLD	Strong Buy -21.0% avg upside 33 analysts	—	+23.6%
URGN Urogen Pharma	Feb 01, 2026	BUY	Strong Buy +13.0% avg upside 16 analysts	$32.00 4.77% Downside	+66.5%
CMPX Compass Therapeutics	Aug 11, 2025	BUY	Strong Buy +373.4% avg upside 19 analysts	$12.00 494.10% Upside	+2.0%
KYMR Kymera Therapeutics	Aug 11, 2025	BUY	Strong Buy +8.9% avg upside 36 analysts	$60.00 33.70% Downside	+138.6%
RLAY Relay Therapeutics	Aug 07, 2025	BUY	Strong Buy +26.4% avg upside 19 analysts	$10.00 36.99% Downside	+354.2%
ARVN Arvinas Holding Company	Aug 06, 2025	BUY	Buy +264.5% avg upside 27 analysts	$15.00 95.64% Upside	+17.9%
ADAPY Adaptimmune Therapeutics	Jul 29, 2025	HOLD	Buy +5712.5% avg upside 10 analysts	—	·
BOLD Boundless Bio Inc.	May 27, 2025	HOLD	Buy +529.4% avg upside 11 analysts	—	+11.5%
MGNX MacroGenics	May 23, 2025	HOLD	Buy +326.2% avg upside 25 analysts	—	+175.5%
IOVA Iovance Biotherapeutics	May 23, 2025	HOLD	Strong Buy +225.8% avg upside 24 analysts	—	+93.8%
LEGN Legend Biotech	May 23, 2025	HOLD	Strong Buy +140.3% avg upside 27 analysts	—	+24.1%
IMCR Immunocore Holdings	Oct 07, 2024	HOLD	Strong Buy +124.3% avg upside 22 analysts	—	-8.8%
GB:0MGB Genmab A/S	Jun 27, 2024	HOLD	Buy +31.5% avg upside 22 analysts	—	·
BOLT Bolt Biotherapeutics	May 14, 2024	HOLD	Buy +480.6% avg upside 7 analysts	—	-81.1%
IMRX Immuneering	Mar 14, 2024	HOLD	Strong Buy +303.9% avg upside 10 analysts	—	+74.1%
ALLO Allogene Therapeutics	Jan 05, 2024	HOLD	Strong Buy +662.1% avg upside 28 analysts	—	-53.8%
XLO Xilio Therapeutics	Dec 07, 2023	BUY	Strong Buy +95.7% avg upside 7 analysts	—	-20.6%
SNDX Syndax Pharmaceuticals	Oct 03, 2023	BUY	Strong Buy +88.8% avg upside 27 analysts	$43.00 126.25% Upside	+23.4%
ACET Adicet Bio	Jun 27, 2023	HOLD	Strong Buy +212.8% avg upside 14 analysts	$20.00 146.98% Upside	-70.6%
ORIC Oric Pharmaceuticals	Mar 21, 2023	BUY	Strong Buy +180.3% avg upside 19 analysts	$15.00 76.64% Upside	+41.4%
FATE Fate Therapeutics	Jan 03, 2023	HOLD	Buy +475.7% avg upside 31 analysts	—	-82.3%
CLLS Cellectis SA	Apr 28, 2021	HOLD	Strong Buy +573.5% avg upside 16 analysts	—	-90.0%
AGIO Agios Pharma	Feb 25, 2021	BUY	Strong Buy +73.2% avg upside 29 analysts	$63.00 84.44% Upside	-50.1%
AMGN Amgen	Sep 18, 2020	HOLD	Buy -11.6% avg upside 57 analysts	—	-0.8%
XNCR Xencor	Aug 06, 2020	BUY	Strong Buy +159.9% avg upside 27 analysts	$44.00 248.08% Upside	-8.4%
NGNE Neurogene	Jun 23, 2020	BUY	Buy +55.5% avg upside 23 analysts	—	-93.5%
PBYI Puma Biotechnology	Sep 17, 2018	BUY	Buy +458.2% avg upside 11 analysts	$85.00 1024.35% Upside	-77.1%
FBRX Forte Biosciences	May 08, 2017	HOLD	Strong Buy +128.0% avg upside 14 analysts	$19.00 6.47% Upside	-37.6%
FR:IPH Innate Pharma SA	Nov 30, 2016	BUY	Strong Buy +449.7% avg upside 5 analysts	—	·
QURE uniQure	Nov 15, 2016	BUY	Strong Buy +16.1% avg upside 29 analysts	$23.00 50.25% Downside	+300.1%
DARE Daré Bioscience	Nov 11, 2016	HOLD	Strong Buy +516.8% avg upside 14 analysts	$15.00 591.26% Upside	-88.8%
ABUS Arbutus Biopharma	Nov 10, 2016	HOLD	Strong Buy +94.1% avg upside 15 analysts	$5.00 9.91% Upside	+69.1%
AFMDQ Affimed	Nov 02, 2016	HOLD	Buy +12648900.0% avg upside 15 analysts	$2.00 1999900.10% Upside	·
IONS Ionis Pharmaceuticals	Oct 09, 2016	HOLD	Strong Buy +13.3% avg upside 43 analysts	$36.00 51.47% Downside	+30.8%
ALNY Alnylam Pharma	Oct 05, 2016	HOLD	Strong Buy +23.6% avg upside 51 analysts	$40.00 85.64% Downside	+23.4%
SYBX Synlogic	Sep 20, 2016	HOLD	Buy +3290.3% avg upside 11 analysts	$1.50 111.27% Upside	-26.0%
KPTI Karyopharm Therapeutics	Sep 06, 2016	BUY	Strong Buy +147.4% avg upside 18 analysts	$18.00 99.63% Upside	+114.6%
NTLA Intellia Therapeutics	Aug 19, 2016	BUY	Buy +151.9% avg upside 37 analysts	—	+2.0%
WVE Wave Life Sciences	Aug 16, 2016	BUY	Strong Buy +260.5% avg upside 28 analysts	$28.00 354.59% Upside	+126.2%
ALKS Alkermes	Oct 06, 2015	BUY	Strong Buy -17.6% avg upside 34 analysts	—	-12.0%
JAZZ Jazz Pharmaceuticals	Aug 06, 2014	BUY	Strong Buy -1.8% avg upside 35 analysts	$181.00 19.33% Downside	+5.5%

🔒 55 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Michael Schmidt — Frequently Asked Questions

How accurate are Michael Schmidt's stock ratings?

Based on the calls 13Foresight could measure, about 51% of Michael's ratings were profitable over a one-year hold, with an average return of +11.5% per rating, or -1.7% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Michael ranked on 13Foresight?

Michael Schmidt is currently ranked #2023 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Michael cover?

Michael most recently has ratings on ENGN, ONC, INCY, ELVN, TNGX, ADCT, AVBP, RVMD, GMAB, IMNM, CTMX, VSTM and 48 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!